Replies to post #116568 on Biotech Values

[DewDiligence]

Correct—the trial was testing Symlin (pramlintide) + metreleptin (not Symlin monotherapy).

[DewDiligence]

AMLN/Takeda officially dump Symlin + Metreleptin obesity program:

http://finance.yahoo.com/news/Amylin-and-Takeda-Discontinue-prnews-2389602892.html?x=0&.v=1

Not surprising given the safety problem encountered five months ago (#msg-60998172).